Per a new Nature Biotech article, scientists have re-engineered Akt1 enzyme to provoke a prolonged immune response to cancer.
This by extension suggests that inhibiting Akt1 has an immune-supressing effect, and perhaps inhibiting other genes in the Akt pathway have the same effect.
Sunday, December 17, 2006
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment